Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Datamonitor Healthcare Reports | Pipeline Insight - Substance Dependence - Part I - Nicotine

Pipeline Insight - Substance Dependence - Part I - Nicotine

"IntroductionThe high prevalence of nicotine dependence, strong uptake of Pfizer’s Chantix (varenicline), and the launch of new innovative therapies will cause the nicotine dependence prescription drug market to grow to $4.6 billion across the seven major markets by 2016. Innovative therapies are set to offer patients a convenient dosing regimen and thereby carrying the potential for improved compliance.ScopeAnalysis of patient potential, unmet needs and clinical trial design in nicotine dependence Overview of the current nicotine dependence market, covering both prescription and OTC products Overview of drugs in late stage clinical development for nicotine dependence Profiles of key compounds in development for use in nicotine dependence, with forecasts of drug revenues to 2016 and insight from key opinion leadersHighlightsNicotine vaccines are the most prevalent drug class in the late-stage pipeline. This represents a move away from nicotine replacement and nicotine agonist therapies, which have historically dominated the market. Datamonitor predicts nicotine vaccine companies will be important players in the market by 2016, led by Novartis’s NIC-002. Nicotine vaccines are designed to prevent nicotine from entering the brain and thus reduce the pleasurable effect of smoking. The utility of vaccines in nicotine dependence lies in the long-term protection they provide along with minimal patient compliance and carry the potential for prophylactic use. With two compounds in late-stage development for the treatment of nicotine dependence, it is evident that Sanofi-Aventis is keen to penetrate this market. Although possessing a similar mechanism of action to Chantix, Datamonitor believes that the drug’s shorter treatment course than the market leader represents a strong competitive advantage. Reasons to PurchaseUnderstand unmet needs and opportunities in this market based on the comments of interviewed key opinion leaders. Benchmark key late-stage nicotine dependence compounds against the current market leader. Assess the seven major market total sales forecasts of key late-stage pipeline drugs; and examine their clinical and commercial potential"

14-Nov-07 Format: PDF Pages: 91
Table of Contents
Price: $7,600.00 / €5,084.40

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions